Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the potential roles of vitamin D in the pathogenesis of alopecia areata and suggests that vitamin D analogs like calcipotriol may have therapeutic potential.

This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

This study reports that combination therapy with oral steroids, anthralin, and minoxidil yielded effective cosmetic responses in 80% of patients with treatment-resistant extensive alopecia areata.

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.

This review discusses the clinical presentations of alopecia areata, introduces guidelines for treatment studies, and explores potential changes in cutaneous innervation, but reports no new clinical results.

In this study, researchers observed that the success of treating hereditary vitamin D–resistant rickets in children depends on the mutation location in the VDR gene, notably with favorable dental development outcomes for those with the p.R391S mutation, despite persistent alopecia.

This study found that mild-to-moderate COVID-19 was not associated with worsening in patients with pre-existing alopecia areata.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

This case report describes a rare instance of alopecia areata linked to nivolumab treatment in a patient with hepatocellular carcinoma.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

This study found that four out of ten patients with alopecia areata experienced some hair regrowth after PUVA therapy, though this treatment should be reserved for those unresponsive to other options due to potential long-term side effects.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

This study reported that patients with alopecia areata or alopecia totalis/universalis have a slightly increased overall cancer risk compared to controls, with specific increases in thyroid, bladder, and prostate cancers depending on the alopecia type.

This case study reports that a combination of PUVA therapy and oral methyl prednisolone initially improved symptoms of a woman's cutaneous T-cell lymphoma but required ongoing treatment due to recurrence.

This study highlights two newly discovered metabolic disorders of biotin, showing distinct skin and hair symptoms and severe complications like acidosis and ketosis.

This study observed that combining nonablative fractional laser treatment with topical minoxidil led to hair regrowth in Chinese alopecia areata patients, noting complete regrowth in some patients and no relapse in the majority at a one-year follow-up, without reported side effects.

This paper reviews Satoyoshi syndrome and suggests diagnostic criteria to differentiate its subtypes, emphasizing the importance of testing alopecia areata patients for antinuclear antibodies, muscle spasms, and diarrhea.

This study reports a novel TRbeta gene mutation associated with resistance to thyroid hormone syndrome, which may contribute to various forms of alopecia in the affected family members.

In this study, researchers observed that purpuric, telangiectatic, lichenoid balanitis was the most common histologic pattern in cases of chronic pseudoerythroplastic balanitis, suggesting a possible link to lichen aureus.

This study observed that patients with alopecia areata had significantly higher serum levels of IL-15 and TNF-α compared to controls, with TNF-α levels particularly elevated in individuals with alopecia totalis, though these biomarkers were not influenced by disease duration or activity.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls.

This review discusses treatment strategies for alopecia areata, emphasizing current immunomodulation approaches but reports no new clinical results.

This report describes a case where the JAK inhibitor tofacitinib led to hair regrowth in a patient with alopecia totalis but also worsened facial acne, highlighting a unique adverse effect.

This study described the clinical and genetic features of two Iranian siblings with hereditary vitamin D resistant rickets, identifying a specific VDR gene mutation contributing to their symptoms.

This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.

This review discusses the economic burden of alopecia areata in adolescents and reports no new results; the authors note that evidence in this area is limited.